Publications
5600 Results
- Journal / Conference
- Bladder Cancer Jun 11;6(2):123-129
- Year
- 2020
- Research Committee(s)
- Genitourinary
- PMID
- PMID32793789
- PMC
- PMC7390592
- Study Number(s)
- S1314
Review of SWOG S1314: Lessons from a randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer [Review]
- Journal / Conference
- J Clin Oncol 38, 2020 (suppl 4; abstr TPS260); ASCO GI Cancers Symposium (January 23-25, 2020, San Francisco, CA)
- Year
- 2020
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/NRG-GI004
A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): COlorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG-GI004/SWOG-S1610)
- Journal / Conference
- ASCO-SITC Clinical Immuno-Oncology Symposium (Feb 6-8, 2020, Orlando, FL), Poster Session (Board #C7)
- Year
- 2020
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1609
Immune related adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants and association with outcome: E1609 study analysis
- Journal / Conference
- J Clin Oncol 38, 2020 (suppl 6; abstr TPS586); ASCO GU Cancers Symposium (Feb 13-15, 2020, San Francisco, CA), trials in progress
- Year
- 2020
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1806
INTACT: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer: SWOG/NRG S1806
- Journal / Conference
- Journal of Urology Vol 203 Issue Suppl 4 April Page: e1092-e1093; (AUA Annual Meeting May 15-18, 2020, Washington DC) #PD52-08, poster
- Year
- 2020
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Changes in blood levels of prostate kallikrein-related and microseminoprotein-beta marker levels follogin 5ARI therapy: data from 500 PCPT-participants
- Journal / Conference
- JCO Oncology Practice Mar;16(3):125-127
- Year
- 2020
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID32074016
What Keeps Patients Out of Clinical Trials? [Editorial]
- Journal / Conference
- Hematologist [Clinical Trials Corner] Sept 1 Vol 17, Issue 5
- Year
- 2020
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (SWOG Intergroup S1826)
- Journal / Conference
- American Journal of Clinical Oncology Mar;43(3):173-179
- Year
- 2020
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID31985516
- PMC
- PMC7280743
- Study Number(s)
- CTSU/R0848
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial
- Journal / Conference
- Supportive Care in Cancer Sep 15. doi: 10.1007/s00520-020-05748-8. Online ahead of print
- Year
- 2020
- Research Committee(s)
- Breast
- PMID
- PMID32929540
- Study Number(s)
- S0307